title: Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.
abstract: Pathological hypersexuality developed in 13 patients with PD and two patients ultimately diagnosed clinically with MSA. Hypersexuality began within 8 months after starting dopamine agonist therapy in 14 of 15 cases, including four on agonist monotherapy. It resolved in the four cases where the agonist was stopped, despite continued levodopa therapy. This was not an isolated behavioral problem in most, with additional compulsive or addictive behaviors coinciding in nine patients (60%). A systematic literature review of pathological hypersexuality in PD revealed similar medication histories; combining these cases with our series, 26 of 29 patients (90%) were on adjuvant dopamine agonists.
authors.affiliation: Department of Neurology, Division of Movement Disorders, Mayo Clinic, Rochester, MN 55905, USA. kklos@tulsacoxmail.com
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Klos
authors.forename: James H
authors.initials: JH
authors.lastname: Bower
authors.forename: Keith A
authors.initials: KA
authors.lastname: Josephs
authors.forename: Joseph Y
authors.initials: JY
authors.lastname: Matsumoto
authors.forename: J Eric
authors.initials: JE
authors.lastname: Ahlskog
mesh_terms: D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D052160:Benzothiazoles; D002396:Catechols / Q000009:adverse effects / Q000627:therapeutic use; D016208:Databases, Factual; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced / Q000523:psychology; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000150:complications* / Q000188:drug therapy; D009570:Nitriles; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy; D000077487:Pramipexole; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced*; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000978:Antiparkinson Agents; D052160:Benzothiazoles; D002396:Catechols; D018491:Dopamine Agonists; D007211:Indoles; D009570:Nitriles; D013844:Thiazoles; C046649:ropinirole; D007980:Levodopa; C071192:entacapone; D000077487:Pramipexole